Allogeneic hematopoietic cell transplantation (allo-HCT) using siblings and matched donors
has the potential for long-term disease control in a subset of high-risk patients with multiple …

Many patients with multiple myeloma (MM) eventually relapse even after allogeneic
hematopoietic cell transplantation (alloHCT) for curative intent. Over the past decade …

Novel agents and autologous transplants have substantially improved the treatment and
quality of life of patients with multiple myeloma; however, myeloma remains an incurable …

Allogeneic (allo) hematopoietic cell transplantation (HCT) currently represents the only
potentially curative therapy for patients affected by multiple myeloma (MM). Up to 30% of …

Background Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative
option for multiple myeloma (MM). We analyzed our experience of allo-HCT in MM and …

Although generally not applied as first-line treatment of multiple myeloma, allogeneic
hematopoietic cell transplantation (allo-SCT) can still be chosen as ultimate escalation …

Allogeneic hematopoietic cell transplant (HCT) may improve long-term multiple myeloma
(MM) control through the graft-versus-myeloma effect. The Blood and Marrow Transplant …

Abstract The EBMT Chronic Malignancies Working Party performed a retrospective analysis
of 215 patients who underwent a second allo-HCT for myeloma between 1994 and 2017 …

Simple Summary Patients with multiple myeloma (MM) refractory to conventional treatment
strategies represent an unmet medical need. Allogeneic stem cell transplantation (allo …

We previously reported initial results in 102 multiple myeloma (MM) patients treated with
sequential high-dose melphalan and autologous hematopoietic cell transplantation followed …